The immunoreactive patient: Rejection and autoimmune disease

Liver Transplantation

Volumn 17, Issue SUPPL. 3, 2011, Pages

  O'Grady, John ^a  

^a KING S COLLEGE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; BASILIXIMAB; CALCINEURIN INHIBITOR; CORTICOSTEROID; CYCLOSPORIN; DACLIZUMAB; INTERFERON; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OKT 3; PREDNISOLONE; STEROID; TACROLIMUS; THYMOCYTE ANTIBODY; URSODEOXYCHOLIC ACID;

ACUTE GRAFT REJECTION; ADD ON THERAPY; ANTIVIRAL THERAPY; ARTERY DISEASE; ARTICLE; AUTOIMMUNE DISEASE; AUTOIMMUNE HEPATITIS; BILE DUCT INJURY; CHRONIC GRAFT REJECTION; CORTICOSTEROID THERAPY; DRUG MEGADOSE; GRAFT REJECTION; GRAFT SURVIVAL; HUMAN; IMMUNOREACTIVITY; IMMUNOSUPPRESSIVE TREATMENT; LIVER TRANSPLANTATION; MULTIPLE CYCLE TREATMENT; PRIMARY BILIARY CIRRHOSIS; PRIMARY SCLEROSING CHOLANGITIS; PRIORITY JOURNAL; STEROID RESISTANT REJECTION; BILIARY CIRRHOSIS; IMMUNOLOGY; METHODOLOGY; REVIEW; RISK FACTOR; SCLEROSING CHOLANGITIS;

CHOLANGITIS, SCLEROSING; GRAFT REJECTION; HEPATITIS, AUTOIMMUNE; HUMANS; IMMUNOSUPPRESSION; LIVER CIRRHOSIS, BILIARY; LIVER TRANSPLANTATION; RISK FACTORS;

EID: 84857179521     PISSN: 15276465     EISSN: 15276473     Source Type: Journal    
DOI: 10.1002/lt.22413     Document Type: Article

References (38)

1. Neil DA, Hübscher SG. Current views on rejection pathology in liver transplantation. Transpl Int 2010;23: 971-983.
2. Haddad EM, McAlister VC, Renouf E, Malthaner R, Kjaer MS, Gluud LL. Cyclosporin versus tacrolimus for liver transplanted patients. Cochrane Database Syst Rev 2006: CD005161.
3. Klein A. Tacrolimus rescue in liver transplant recipients with refractory rejection or intolerance or malabsorption of cyclosporine. The US Multicenter FK506 Liver Study Group. Liver Transpl Surg 1999;5: 502-508.
4. Hebert MF, Ascher NL, Lake JR, Emond J, Nikolai B, Linna TJ, Roberts JP. Four-year follow-up of mycophenolate mofetil for graft rescue in liver allograft recipients. Transplantation 1999;67: 707-712.
5. Aw MM, Verma A, Rela M, Heaton N, Mieli-Vergani G, Dhawan A. Long-term outcome of mycophenolate mofetil rescue therapy for resistant acute allograft rejection in pediatric liver transplant recipients. Liver Transpl 2008; 14: 1303-1308.
6. Fung JJ, Demetris AJ, Porter KA, Iwatsuki S, Gordon RD, Esquivel CO, et al. Use of OKT3 with cyclosporine and steroids for reversal of acute kidney and liver allograft rejection. Nephron 1987;46(suppl 1): S19-S33.
7. Platz KP, Mueller AR, Zytowski M, Lemmens P, Lobeck H, Neuhaus P. Management of acute steroid-resistant rejection after liver transplantation. World J Surg 1996; 20: 1052-1058.
8. Solomon H, Gonwa TA, Mor E, Holman MJ, Gibbs J, Watemberg I, et al. OKT3 rescue for steroid-resistant rejection in adult liver transplantation. Transplantation 1993;55: 87-91.
9. McDiarmid SV, Busuttil RW, Terasaki P, Vargas JH, Ament ME. OKT3 treatment of steroid-resistant rejection in pediatric liver transplant recipients. J Pediatr Gastroenterol Nutr 1992;14: 86-91.
10. Bijleveld CG, Klompmaker IJ, van den Berg AP, Gouw AS, Hepkema BG, Haagsma EB, et al. Incidence, risk factors, and outcome of antithymocyte globulin treatment of steroid-resistant rejection after liver transplantation. Transpl Int 1996;9: 570-575.
11. Schmitt TM, Phillips M, Sawyer RG, Northup P, Hagspiel KD, Pruett TL, Bonatti HJ. Anti-thymocyte globulin for the treatment of acute cellular rejection following liver transplantation. Dig Dis Sci 2010;55: 3224-3234.
12. Ueda D, Hori T, Nguyen JH, Uemoto S. Muromonab- CD3 therapy for refractory rejections after liver transplantation: a single-center experience during two decades in Japan. J Hepatobiliary Pancreat Sci 2010;17: 885-891.
13. Orr DW, Portmann BC, Knisely AS, Stoll S, Rela M, Muiesan P, et al. Anti-interleukin 2 receptor antibodies and mycophenolate mofetil for treatment of steroid-resistant rejection in adult liver transplantation. Transplant Proc 2005;37: 4373-4379.
14. Aw MM, Taylor RM, Verma A, Parke A, Baker AJ, Hadzic D, et al. Basiliximab (Simulect) for the treatment of steroid- resistant rejection in pediatric liver transplant recipients: a preliminary experience. Transplantation 2003; 75: 796-799.
15. Blakolmer K, Seaberg EC, Batts K, Ferrell L, Markin R, Wiesner R, et al. Analysis of the reversibility of chronic liver allograft rejection implications for a staging schema. Am J Surg Pathol 1999;23: 1328-1339.
16. Jain A, Demetris AJ, Manez R, Tsamanadas AC, Van Thiel D, Rakela J, et al. Incidence and severity of acute allograft rejection in liver transplant recipients with alfa interferon. Liver Transpl Surg 1998;4: 197-203.
17. Gurusamy KS, Tsochatzis E, Davidson BR, Burroughs AK. Antiviral prophylactic intervention for chronic hepatitis C virus in patients undergoing liver transplantation. Cochrane Database Syst Rev 2010: CD006573.
18. Wang CS, Ko HH, Yoshida EM, Marra CA, Richardson K. Interferon-based combination anti-viral therapy for hepatitis C virus after liver transplantation: a review and quantitative analysis. AmJ Transplant 2006;6: 1586-1599.
19. Walter T, Dumortier J, Guillaud O, Hervieu V, Paliard P, Scoazec JY, Boillot O. Rejection under alpha interferon therapy in liver transplant recipients. Am J Transplant 2007;7: 177-184.
20. Stanca CM, Fiel MI, Kontorinis N, Agarwal K, Emre S, Schiano TD. Chronic ductopenic rejection in patients with recurrent hepatitis C virus treated with pegylated interferon alfa-2a and ribavirin. Transplantation 2007; 84: 180-186.
21. Angelico M, Petrolati A, Lionetti R, Lenci I, Burra P, Donato MF, et al. A randomized study on peg-interferon alfa-2a with or without ribavirin in liver transplant recipients with recurrent hepatitis C. J Hepatol 2007;46: 1009-1017.
22. Saab S, Kalmaz D, Gajjar NA, Hiatt J, Durazo F, Han S, et al. Outcomes of acute rejection after interferon therapy in liver transplant recipients. Liver Transpl 2004;10: 859-867.
23. Fernández I, Ulloa E, Colina F, Abradelo M, Jiménez C, Gimeno A, et al. Incidence, risk factors, and outcome of chronic rejection during antiviral therapy for posttransplant recurrent hepatitis C. Liver Transpl 2009;15: 948-955.
24. Stravitz RT, Shiffman ML, Sanyal AJ, Luketic VA, Sterling RK, Heuman DM, et al. Effects of interferon treatment on liver histology and allograft rejection in patients with recurrent hepatitis C following liver transplantation. Liver Transpl 2004;10: 850-858.
25. Berardi S, Lodato F, Gramenzi A, D'Errico A, Lenzi M, Bontadini A, et al. High incidence of allograft dysfunction in liver transplanted patients treated with pegylatedinterferon alpha-2b and ribavirin for hepatitis C recurrence: possible de novo autoimmune hepatitis? Gut 2007;56: 237-242.
26. Merli M, Gentili F, Giusto M, Attili AF, Corradini SG, Mennini G, et al. Immune-mediated liver dysfunction after antiviral treatment in liver transplanted patients with hepatitis C: allo or autoimmune de novo hepatitis? Dig Liver Dis 2009;41: 345-349.
27. Silveira MG, Talwalkar JA, Lindor KD, Wiesner RH. Recurrent primary biliary cirrhosis after liver transplantation. Am J Transplant 2010;10: 720-726.
28. Rowe IA, Webb K, Gunson BK, Mehta N, Haque S, Neuberger J. The impact of disease recurrence on graft survival following liver transplantation: a single centre experience. Transpl Int 2008;21: 459-465.
29. Charatcharoenwitthaya P, Pimentel S, Talwalkar JA, Enders FT, Lindor KD, Krom RA, Wiesner RH. Long-term survival and impact of ursodeoxycholic acid treatment for recurrent primary biliary cirrhosis after liver transplantation. Liver Transpl 2007;13: 1236-1245.
30. Neuberger J, Gunson B, Hubscher S, Nightingale P. Immunosuppression affects the rate of recurrent primary biliary cirrhosis after liver transplantation. Liver Transpl 2004;10: 488-491.
31. Montano-Loza AJ, Wasilenko S, Bintner J, Mason AL. Cyclosporine A protects against primary biliary cirrhosis recurrence after liver transplantation. Am J Transplant 2010;10: 852-858.
32. Vera A, Moledina S, Gunson B, Hubscher S, Mirza D, Olliff S, Neuberger J. Risk factors for recurrence of primary sclerosing cholangitis of liver allograft. Lancet 2002;360: 1943-1944.
33. Alabraba E, Nightingale P, Gunson B, Hubscher S, Olliff S, Mirza D, Neuberger J. A re-evaluation of the risk factors for the recurrence of primary sclerosing cholangitis in liver allografts. Liver Transpl 2009;15: 330-340.
34. Kugelmas M, Spiegelman P, Osgood MJ, Young DA, Trotter JF, Steinberg T, et al. Different immunosuppressive regimens and recurrence of primary sclerosing cholangitis after liver transplantation. Liver Transpl 2003;9: 727-732.
35. Duclos-Vallée JC, Sebagh M, Rifai K, Johanet C, Ballot E, Guettier C, et al. A 10 year follow up study of patients transplanted for autoimmune hepatitis: histological recurrence precedes clinical and biochemical recurrence. Gut 2003;52: 893-897.
36. Mieli-Vergani G, Vergani D. De novo autoimmune hepatitis after liver transplantation. J Hepatol 2004;40: 3-7.
37. Miyagawa-Hayashino A, Haga H, Egawa H, Hayashino Y, Sakurai T, Minamiguchi S, et al. Outcome and risk factors of de novo autoimmune hepatitis in living-donor liver transplantation. Transplantation 2004;78: 128-135.
38. Venick RS, McDiarmid SV, Farmer DG, Gornbein J, Martin MG, Vargas JH, et al. Rejection and steroid dependence: unique risk factors in the development of pediatric posttransplant de novo autoimmune hepatitis. Am J Transplant 2007;7: 955-963.